Ear Infections (Topical)
Otiprio is a sterile, preservative-free, otic suspension that is administered as a single-dose to the external ear canal of each affected ear by a healthcare professional.
Researchers found that in the study cohort of 96,595 children, those exposed to quinolone ear drops had an increased risk of perforation
Doctors conducted a retrospective review of a random selection of 250 patients aged ≤18 years with AOM in the emergency department.
They measured the rates of clinical response on the basis of signs and symptomatic response, recurrence, nasopharyngeal colonization, and episode outcomes.
Laboratorios SALVAT S.A. and Arbor announced the launch of Otovel (ciprofloxacin and fluocinolone) otic solution, the first antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials.
In a recent study published in Pediatrics, researchers suggested that increased breastfeeding, vaccine administration, and lower rates of smoking may be major factors in the reduced rate of ear infections in babies.
Inflammation from bacterial infections may increase susceptibility to aminoglycoside-linked hearing impairment by increasing the uptake of the antibiotic into the inner ear.
As part of the Unapproved Drugs Initiatives, the Food and Drug Administration (FDA) announced it will take enforcement action against companies that manufacture and/or distribute unapproved prescription otic products labeled to relieve ear pain, infection, and inflammation.
Par announced the launch of Cortisporin-TC (colistin sulfate, neomycin sulfate, thonzonium bromide, hydrocortisone acetate) Otic Suspension for the treatment of otitis externa caused by susceptible organisms and for the treatment of mastoidectomy and fenestration cavities caused by susceptible organisms.
A drug to treat stroke showed efficacy in treating middle-ear infections by suppressing mucus overproduction, improving bacterial clearance, and reducing hearing loss, researchers from the Georgia State University and University of Rochester reported.
The Food and Drug Administration (FDA) has approved Xtoro (finafloxacin otic suspension; Alcon) for the treatment of acute otitis externa (also known as swimmer's ear) caused by Pseudomonas aeruginosa and Staphylococcus aureus.
Otonomy announced positive results from two Phase 3 trials of AuriPro (ciprofloxacin) for intra-operative treatment of middle ear effusion in pediatric patients requiring tympanostomy tube placement surgery.
Over $11.1 million worth of unapproved drugs have been seized by the U.S. marshals per request of the FDA and the U.S. Attorney for the Southern District of Ohio.
For young children with undifferentiated acute respiratory infections (ARIs), current evidence does not support the use of antibiotics to prevent ear infections or pneumonia.
Children with acute tympanostomy-tube otorrhea have significantly better outcomes after treatment with antibiotic-glucocorticoid eardrops compared with oral antibiotics or initial observation.
A systematic review of the comparative efficacy of surgical treatments for otitis media with effusion (OME) in children has been published online Jan. 6 in Pediatrics.
The first evidence-based clinical practice guideline on tympanostomy tubes in children aged 6 months to 12 years has been published.
The American Academy of Pediatrics (AAP) recently published revisions to the 2004 acute otitis media guidelines in the March issue of Pediatrics.